Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11267099 | 0.69 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL10401029 | 0.68 | HTR3A (0.47) | HTR3EHTR3BHTR3AHTR4HTR3D | |
| SCHEMBL20247440 | 0.68 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDSMN1; SMN2ADRA2A | |
| Hydrochloric Acid SCHEMBL7279312 | 0.68 | DRD2 (0.56) | ALDH1A1KDM4ESMN1; SMN2ADRA2ACYP2D6 | |
| SCHEMBL11268155 | 0.68 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDSMN1; SMN2ADRA2A | |
| SCHEMBL1209977 | 0.66 | ALDH1A1 (0.69) | ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A | |
| SCHEMBL3639066 | 0.66 | PARP1 (0.57) | ALDH1A1KDM4EHPGDSMN1; SMN2HTR4 | |
| SCHEMBL1211688 | 0.66 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDSMN1; SMN2KMT2A | |
| SCHEMBL2442303 | 0.66 | KDM4E (0.64) | ALDH1A1KDM4EHPGDSMN1; SMN2CYP2D6 | |
| SCHEMBL1209964 | 0.66 | LMNA (0.72) | ALDH1A1SMN1; SMN2KMT2ALMNASLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6517811-B2 | Diagnosing a mammal for presence of a tumor by administering compounds such as 125-I-(2-piperidinylaminoethyl)-4-iodobenzamide which have an affinity for cell surface sigma receptors | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6447748-B1 | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2002-09-10 | — | — | US | disclosed |
| US-20010006619-A1 | Compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2001-07-05 | — | — | US | disclosed |
| US-6015543-A | DIAGNOSIS OF TUMORS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 2000-01-18 | — | — | US | disclosed |
| US-5993777-A | Benzamide compounds for cancer imaging and therapy | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-11-30 | — | — | US | disclosed |
| US-5911970-A | ANTITUMOR AGENTS AND ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1999-06-15 | — | — | US | disclosed |
| WO-1996032968-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1996-10-24 | — | — | WO | disclosed |
| EP-0650372-A4 | COMPOUNDS FOR CANCER IMAGING AND THERAPY. | JOHN CHRISTY S (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0650372-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN, Christy S. (US) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994026314-A1 | COMPOUNDS FOR CANCER IMAGING AND THERAPY | JOHN CHRISTY S (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010006619-A1 | Compounds for cancer imaging and therapy | SIGMAR1, TMEM97, ADRB3 | ALDH1A1 713/4885KDM4E 4422/4885HPGD 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.